Abstract
Background
Data on outcomes of microsatellite instable and/or mismatch repair deficient (dMMR/MSI)
digestive non-colorectal tumors are limited.
Aims
To evaluate overall survival (OS) of patients with dMMR/MSI digestive non-colorectal
tumor.
Methods
All consecutive patients with a dMMR/MSI digestive non-colorectal tumor were included
in this French retrospective multicenter study.
Results
One hundred and sixteen patients were included with a mean age of 63.6 years and 32.6%
with a Lynch syndrome. Most tumors were oesophago-gastric (54.3%) or small bowel (32.8%)
adenocarcinomas and at a localized stage at diagnosis (86.7%). In patients with localized
tumors and R0 resection, median OS was 134.0 ± 64.2 months. Median disease-free survival
(DFS) was 100.3 ± 65.7 months. Considering oesophago-gastric tumors, median DFS was
improved when chemotherapy was added to surgery (not reached versus 22.8 ± 10.0 months,
p = 0.03). In patients with advanced tumors treated by chemotherapy, median OS was
14.2 ± 1.9 months and median progression-free survival was 7.4 ± 1.6 months.
Conclusion
dMMR/MSI digestive non-colorectal tumors are mostly diagnosed at a non-metastatic
stage with a good prognosis. Advanced dMMR/MSI digestive non-colorectal tumors have
a poor prognosis with standard chemotherapy.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer.Sci Rep. 2021; 11: 12880
- Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.World J Gastroenterol. 2014; 20: 4230-4243
- Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.J Clin Oncol. 2010; 28: 3219-3226
- Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.N Engl J Med. 2003; 349: 247-257
- Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies.Clin Cancer Res. 2014; 20: 5322-5330
- Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: an AGEO retrospective multicenter study.Int J Cancer. 2020; 147: 285-296
- Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial.JAMA Oncol. 2017; 3: 1197-1203
- The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: results from a large cohort with subgroup analyses.Int J Cancer. 2015; 137: 819-825
- Microsatellite instability and programmed cell death-ligand 1 expression in stage II/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study.Ann Surg. 2019; 270: 309-316
- Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer.J Clin Oncol. 2019; 37: 3392-3400
- Panel gene profiling of small bowel adenocarcinoma, results from the NADEGE prospective cohort.Int J Cancer. 2021; 148: 1731-1742
- Prevalence of microsatellite instability in intraductal papillary mucinous neoplasms of the pancreas.Gastroenterology. 2018; 154: 1061-1065
- PD-1 blockade in tumors with mismatch-repair deficiency.N Engl J Med. 2015; 372: 2509-2520
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science. 2017; 357: 409-413
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.Nat Med. 2018; 24: 1449-1458
- Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study.J Clin Oncol. 2020; 38: 1-10
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.Nat Med. 2020; 26: 566-576
- Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer.ESMO Open. 2021; 6100120
- Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR.Gastroenterology. 2002; 123: 1804-1811
- Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors.J Clin Oncol. 2006; 24: 241-251
- Lynch syndrome: when pathologist and clinician have the opportunity to reduce the risk of developing cancer.Rev Med Suisse. 2011; 7: 1502-1506
- Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers.Surgery. 2006; 139: 347-356
- MSI phenotype and MMR alterations in familial and sporadic gastric cancer.Int J Cancer. 2011; 128: 1606-1613
- Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial.J Clin Oncol. 2017; 35: 4004
- DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma.Hum Pathol. 2019; 85: 18-26
- Small bowel adenocarcinoma: results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients.Int J Cancer. 2020; 147: 967-977
- Distinct clinical features and outcomes of gastric cancers with microsatellite instability.Mod Pathol. 2002; 15: 632-640
- Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.Ann Oncol. 2010; 21: 1786-1793
Article info
Publication history
Published online: April 06, 2022
Accepted:
March 18,
2022
Received:
December 5,
2021
Identification
Copyright
© 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
